Menopause and metabolic syndrome;Menopausa e síndrome metabólica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 2, 2014, Pages 91-96

  Meirelles, Ricardo M R ^a  

^a Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

Author keywords

Estrogens; Hormone therapy in the menopause; Insulin resistance; Menopause; Metabolic syndrome

Indexed keywords

ESTRADIOL; ESTROGEN;

COMPLICATION; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIA; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE; MENOPAUSE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; WOMEN'S HEALTH;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ESTRADIOL; ESTROGENS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIFE STYLE; MENOPAUSE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; WOMEN'S HEALTH;

EID: 84900536984     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000002909     Document Type: Article

References (60)

1. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factors in women. Eur Heart J. 2002;23:1738-52.
2. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447-52.
3. Lin JW, Caffrey JL, Chang MH, Lin YS. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality- -cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab. 2010;95:4258-67.
4. Deibert P, Konig D, Vitolins MZ, Landmann U, Frey I, Zahradnik HP, et al. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutr J. 2007;6:31.
5. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65:262-6.
6. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadifard N, Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetol Metab Syndr. 2010;2:59.
7. Kim HM, Park J, Ryu SY, Kim J. The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey, 2001. Diabetes Care. 2007;30:701-6.
8. Pandey S, Srinivas M, Agashe S, Joshi J, Galvankar P, Prakasam CP, et al. Menopause and metabolic syndrome: a study of 498 urban women from western India. J Midlife Health. 2010;1:63-9.
9. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-11.
10. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
11. Wamala SP, Lynch J, Horsten M, Mittleman MA, Schenck- Gustafsson K, Orth-Gomer K. Education and the metabolic syndrome in women. Diabetes Care. 1999;22:1999-2003.
12. Pi-Sunyer X. The metabolic syndrome: how to approach differing definitions. Med Clin North Am. 2007;91:1025-40, vii.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
14. Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas. 2009;62:362-5.
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
16. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-8.
17. Oliveira JE, Milech A, Franco LJ. The prevalence of diabetes in Rio de Janeiro, Brazil. The Cooperative Group for the Study of Diabetes Prevalence in Rio De Janeiro. Diabetes Care. 1996;19:663-6.
18. Stevenson JC. Type and route of estrogen administration. Climacteric. 2009;12 Suppl 1:86-90.
19. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
20. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
21. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57:505-28.
22. Chu MC, Cosper P, Orio F, Carmina E, Lobo RA. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol. 2006;194:100-4.
23. Kim JH, Kim SH, Im JA, Lee DC. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas. 2010;67:67-71.
24. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes. (Lond) 2010;34(6):949-59.
25. Rebuffe-Scrive M, Eldh J, Hafstrom LO, Bjorntorp P. Metabolism of mammary, abdominal, and femoral adipocytes in women before and after menopause. Metabolism. 1986;35:792-7.
26. Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp Biol Med (Maywood). 2004;229:1127-35.
27. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr. 1992;55:950-4.
28. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. Menopause. 2000;7:96-104.
29. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991;40:1323-6.
30. Poehlman ET, Tchernof A. Traversing the menopause: changes in energy expenditure and body composition. Coron Artery Dis. 1998;9:799-803.
31. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565-74.
32. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2046-53.
33. Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol. 2011;22:2687-92.
34. Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996;20:1027-32.
35. Jouyandeh Z, Nayebzadeh F, Qorbani M, Asadi M. Metabolic syndrome and menopause. J Diabetes Metab Disord. 2013;12:1.
36. Klein S. Outcome success in obesity. Obes Res. 2001;9 Suppl 4:354S-8S.
37. Ryan AS, Pratley RE, Goldberg AP, Elahi D. Resistive training increases insulin action in postmenopausal women. J Gerontol A Biol Sci Med Sci. 1996;51:M199-205.
38. Cornu C, Mercier C, French P, Bully C, Pugeat M, Cousin P, et al. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Maturitas. 2000;37:95-104.
39. Gaspard UJ, Gottal JM, Vandenbrule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas. 1995;21:171-8.
40. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:83-90.
41. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
42. Hidalgo LA, Chedraui PA, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol. 2006;22:447-54.
43. Hirvonen E, Lipasti A, Malkonen M, Karkkainen J, Nuntila J, Timonen H, et al. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in postmenopausal women. Maturitas 1987;9:69-79.
44. Aygen EM, Basbug M, Tayyar M, Kaya E. The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period. Gynecol Endocrinol 1998;12:267-72.
45. Moorjani S, Dupont A, Labrie F, De Lignieres B, Cusan L, Dupont P, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab. 1991;73:373-9.
46. Kuba VM, Teixeira MA, Meirelles RM, Assumpcao CR, Costa OS. Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol. Climacteric. 2012;16:54-61.
47. Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J Womens Health (Larchmt). 2006;15:584-90.
48. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double- blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-53.
49. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591-602.
50. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-9.
51. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA. 2002;288:321-33.
52. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013;20:254-60.
53. Beaufils M. [Hypertension in women after menopause]. Presse Med. 2006;35:1055-60.
54. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension. 2004;43:918-23.
55. Belo NO, Sairam MR, Dos Reis AM. Impairment of the natriuretic peptide system in follitropin receptor knockout mice and reversal by estradiol: implications for obesity-associated hypertension in menopause. Endocrinology. 2008;149:1399-406.
56. Nichols M, Robinson G, Bounds W, Newman B, Guillebaud J. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception. 1993;47:367-76.
57. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab. 2004;15:277-85.
58. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas. 2004;49:189-203.
59. Mueck AO. Hypertension and HRT. Int Congr Ser. 2012;1229:115-22.
60. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001;103:2903-8.